The life sciences sector is one of the most innovative and resilient parts of the global economy. The conditions that underpin that success, however, are changing. Of course, scientific breakthroughs continue to drive progress, but they are no longer the sole determinants of growth for operators. Success is now defined more by how effectively organisations navigate pricing pressures, deploy capital, and scale that innovation.
At the same time, consumer behaviour is evolving, with patients increasingly willing to pay out of pocket for treatments that offer tangible quality-of-life benefits. This is accelerating the rise of more consumer-centric healthcare delivery. The industry must therefore balance scale-driven growth with affordability and delivery constraints.
Financing becomes a strategic advantage in a changing sector
We see a more complex and flexible financing landscape, with traditional funding models joined by private credit and structured capital providers, royalty and revenue-contingent financing, sovereign and long-duration capital, and public-private funding partnerships.
This kind of innovation in financing is both expanding the capital pool and redistributing risk with far greater precision. Structures like royalty and milestone driven financings are attracting new investors, particularly into the underfunded space between clinical validation and commercial scale, where traditional capital is often constrained. Financing strategies vary according to specific assets, risks and development phases – equity continues to dominate early-stage, high-risk innovation, while structured and non-dilutive capital is increasingly used at later stages.
At the same time, increased competition for high-quality assets and the amount of dry powder in the market are driving more sophisticated structures that disaggregate risk and allocate it more precisely across the value chain.
Private equity in healthcare remains highly attractive, but the investment environment has become more disciplined on pricing, more selective in asset selection and more complex in execution. The market is increasingly bifurcated, with high-quality, defensible assets continuing to attract strong demand, while less differentiated businesses face longer processes, valuation gaps and more structured deal terms.
But funding gaps remain, particularly in Europe, where companies often struggle to secure capital between early discovery and clinical proof of concept. In this environment, capital strategy has become a core capability and a key competitive differentiator.
AI is reshaping the way the sector develops drugs and delivers care
The past decade saw innovation concentrated in specialty areas such as oncology and immunology. Today, partly driven by the success of GLP-1 therapies, the industry is shifting back toward high-prevalence, large-scale disease areas with broader patient populations. With this increased scale come delivery challenges that require more scalable, digital-first care models.
More broadly, artificial intelligence is reshaping life sciences and healthcare across the value chain. It is accelerating drug discovery and development, enhancing diagnostics and enabling personalised medicine, reducing administrative burden, improving clinical workflows, and unlocking new models of patient engagement and care delivery.
What stands out is not only AI’s capability, but the speed of its adoption by clinicians, organisations and patients. This rapid uptake is driven by immediate, tangible benefits such as time savings and decision support. Its value is also becoming clearer in less visible areas, including workflow automation, data structuring and interoperability, and operational efficiency across healthcare systems.
However, a gap remains between adoption and measurable financial impact, and challenges around trust, validation and integration persist. Competitive advantage will therefore depend on practical, scalable implementation and demonstrable outcomes.
Mobilising data and reacting to regulation will define the next winners
Looking ahead, we anticipate the way life sciences create value to continue evolving. Much of healthcare data remains unstructured and underutilised, and unlocking it is essential to enabling AI at scale. At the same time, the rise of foundation models and agentic AI is changing how solutions are built, favouring platforms and ecosystems over standalone tools. The ability to embed it into clinical workflows and healthcare systems will ultimately determine real-world impact.
Regulation is also emerging as a defining variable. Legislative frameworks are struggling to keep pace with technological change, and fragmentation across geographies is increasing complexity. Europe, in particular, faces this challenge.
Undoubtedly, the life sciences sector is becoming more demanding. The next generation of leaders will be defined more than anything by their ability to navigate complexity across markets, capital and technology with greater speed, precision and effectiveness than their peers.